A US-based KOL reviews real-world management of neuroendocrine tumors, highlighting site-based segmentation, frontline somatostatin analog use and heterogeneous second-line decision-making. The interview explores PRRT versus everolimus and liver-directed approaches and evaluates beta and alpha radioligands in both naïve and post-PRRT settings.

This interview was conducted on November 14, 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.